Abstract: A respirator comprising: an air supply unit arranged to deliver air at its output.

Abstract: Systems, methods and apparatus for providing an availability status associated with a facility. One system includes an illumination indicator, a thermal grid array sensor, and an electronic controller. The thermal grid array sensor is configured to sense an outside region, an entryway region, and an inside region associated with a facility subsystem. The electronic controller is configured to determine the current availability status as unavailable responsive to the thermal grid array sensor detecting a heat signature in the outside region, subsequently in the entryway region, and subsequently in the inside region. The electronic controller is also configured to determine the current availability status as available responsive to the thermal grid array sensor detecting the heat signature in the inside region, subsequently in the entryway region, and subsequently in the outside region.

Abstract: Systems, methods and apparatus for providing an availability status associated with a facility. One system includes an illumination indicator, a thermal grid array sensor, and an electronic controller. The thermal grid array sensor is configured to sense an outside region, an entryway region, and an inside region associated with a facility subsystem. The electronic controller is configured to determine the current availability status as unavailable responsive to the thermal grid array sensor detecting a heat signature in the outside region, subsequently in the entryway region, and subsequently in the inside region. The electronic controller is also configured to determine the current availability status as available responsive to the thermal grid array sensor detecting the heat signature in the inside region, subsequently in the entryway region, and subsequently in the outside region.

Abstract: Systems, methods and apparatus for providing an availability status associated with a facility. One system includes an illumination indicator, a thermal grid array sensor, and an electronic controller. The thermal grid array sensor is configured to sense an outside region, an entryway region, and an inside region associated with a facility subsystem. The electronic controller is configured to determine the current availability status as unavailable responsive to the thermal grid array sensor detecting a heat signature in the outside region, subsequently in the entryway region, and subsequently in the inside region. The electronic controller is also configured to determine the current availability status as available responsive to the thermal grid array sensor detecting the heat signature in the inside region, subsequently in the entryway region, and subsequently in the outside region.

Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

Abstract: A system and method of hotel tray and trolley retrieval including a notification device and a computing system wirelessly connected by a network. When in use, the notification device is assigned to a room number of a hotel room via software running on the computing system. A tray and/or a trolley is delivered to the hotel room with the notification device. The hotel patron may then activate the activation device of the notification device. The notification device then sends a wireless communication to the computing system over the network indicating that the tray and/or trolley is ready for pickup from the hotel room.

Abstract: A system and method for providing real-time database driven e-flyers to real estate agents. An e-flyer distribution server generates an e-flyer based on listing details provided by a real estate agent. The e-flyer distribution server utilizes a real-estate-agent database to distribute the e-flyer to real estate agents that are identified based on their target region. Real estate agents utilize an e-flyer presentation module on a mobile computing device to receive and view the e-flyers that are provided to that real estate agent. The real estate agent can interact with the e-flyer to perform additional actions associated with the e-flyer.

Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

Abstract: A system and method of hotel tray and trolley retrieval including a notification device and a computing system wirelessly connected by a network. When in use, the notification device is assigned to a room number of a hotel room via software running on the computing system. A tray and/or a trolley is delivered to the hotel room with the notification device. The hotel patron may then activate the activation device of the notification device. The notification device then sends a wireless communication to the computing system over the network indicating that the tray and/or trolley is ready for pickup from the hotel room.

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: ?wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing

Abstract: A closure assembly is provided including a closure having a closure hinge, a closure hinge cover and a linkage between the closure and the cover. When the closure is in a closed position, the cover extends in a plane overlying the closure hinge. When the closure is an opened position the cover is displaced to an open position to allow the closure hinge to pass through the plane that the cover assumes when the closure is closed.

Abstract: A closure assembly is provided including a closure having a closure hinge, a closure hinge cover and a linkage between the closure and the cover. When the closure is in a closed position, the cover extends in a plane overlying the closure hinge. When the closure is an opened position the cover is displaced to an open position to allow the closure hinge to pass through the plane that the cover assumes when the closure is closed.

Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing